/news/b/pressreleases/archive/2017/03/22/hepatera-completed-patient-recruitment-for-clinical-trials-of-an-innovative-drug-against-hepatitis-b-with-delta-agent.aspxHepatera LLC, a biotechnology company of Maxwell Biotech Group and a resident of the Skolkovo Foundation Biomed Cluster, has completed the patient recruitment for phase 2b clinical trials of Myrcludex B innovative medical drug. Hepatera is implementing7.x Production